摘要
目的探讨化疗患者完全植入性静脉输液港相关血栓形成的影响因素,为临床输液港植入护理方案的制定提供参考。方法回顾性收集278例乳腺癌化疗患者输液港相关血栓形成相关因素及血栓观察结果情况,进行非条件多因素Logistic回归分析,探索血栓形成的危险因素。结果输液港相关血栓形成的发生率31.3%(n=87,其中无症状血栓27.3%,症状性血栓4.0%)。血液高凝状态、临床分期为Ⅰ期、接受高密度化疗(ddAC-ddT)及FAC-T化疗方案的患者输液港相关血栓形成的发生率较高,是其主要的危险因素(P<0.05,P<0.01)。结论乳腺癌化疗患者输液港相关血栓形成发生率较高,与患者血凝状态、肿瘤分期及化疗方案有关,临床上对高危患者应加强监测,以降低血栓形成发生率。
Objective To explore the risk factors of venous thrombosis associated with totally implantable venous access ports system(TIVAPS),and to provide references for formulation of nursing plans of TIVAPS.Methods Totally,278 breast cancer patients who were on chemotherapy through TIVAPS were retrospectively included and such data as the incidence of TIVAPS-related venous thrombosis,potential factors associated to venous thrombosis were collected.Unconditional Logistic regression analysis was run to explore the risk factors of TIVAPS-related venous thrombosis.Results The incidence rate of TIVAPS-related venous thrombosis was 31.3%(n=87),with 27.3%developing asymptomatic thrombus and 4.0%developing symptomatic thrombus.The patients who developed hypercoagulable states,had first stage cancer,and received high-density chemotherapy regimen of ddAC-ddT or FAC-T presented significantly higher incidence rate of thrombosis;the 4 factors contributed to TIVAPS-related venous thrombosis(P<0.05,P<0.01).Conclusion The breast cancer patients had high incidence rate of TIVAPS-related venous thrombosis,which was associated to hypercoagulable states,advanced clinical stages and chemotherapy regimens.Patients at high risk should be closely monitored in an effort to reduce incidence rate of TIVAPS-related venous thrombosis.
作者
毛美芬
徐文亚
高雪娟
顾迪
贺春华
陈华
华艳萍
Mao Meifen;Xu Wenya;Gao Xuejuan;Gu Di;He Chunhua;Chen Hua;Hua Yanping(Department of Breast Surgery,The First People's Hospital of Changzhou,Changzhou 213003,China)
出处
《护理学杂志》
CSCD
北大核心
2019年第11期33-35,共3页
Journal of Nursing Science
关键词
乳腺癌
输液港
化疗
血栓形成
危险因素
血液高凝状态
化疗方案
肿瘤分期
breast cancer
totally implantable venous access ports
chemotherapy
thrombosis
risk factors
hypercoagulable states
chemotherapy regimens
clinical staging of cancer